Buscar





Buscar





Mercado
/
Acciones
/
nasdaq-sdgr
/

Schrodinger Inc

SDGR

Añadir a la lista de seguimiento

11.950USD

-0.670-5.31%

Cierre 05/15, 16:00（ET）Cotizaciones retrasadas 15 min

880.47MCap. mercado

PérdidaP/E TTM



Schrodinger Inc

11.950

-0.670-5.31%

Descripción general Finanzas Discusiones Análisis Compañía

Descripción general

Finanzas

Discusiones

Análisis

Compañía

Más Datos de Schrodinger Inc Compañía

Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.

Información de Schrodinger Inc



Símbolo de cotizaciónSDGR

Nombre de la empresaSchrodinger Inc

Fecha de salida a bolsaFeb 06, 2020

Director ejecutivoFarid (Ramy Farid)

Número de empleados891

Tipo de seguridadOrdinary Share

Fin del año fiscalFeb 06

Dirección1540 Broadway

CiudadNEW YORK

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal10036

Teléfono15032991150

Sitio Webhttps://www.schrodinger.com

Símbolo de cotizaciónSDGR

Fecha de salida a bolsaFeb 06, 2020

Director ejecutivoFarid (Ramy Farid)

Ejecutivos de Schrodinger Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Richard A. Friesner, Ph.D.

Director

1.40M

+0.19%

Mr. Kenneth Patrick (Patrick) Lorton

Executive Vice President, Chief Operating Officer - Software

72.66K

+50.36%

Ms. Margaret Dugan, M.D.

Chief Medical Officer

24.57K

-5.68%

Dr. Rosana Kapeller-Libermann, M.D., Ph.D.

Independent Director

11.25K

-8.86%

Mr. Arun Oberoi

Independent Director

11.25K

-8.86%

Ms. Yvonne Tran, J.D.

Chief People Officer, Executive Vice President, Chief Legal Officer

10.49K

-402.13%

Ms. Bridget Anne Van Kralingen

Independent Director

3.33K

-245.00%

Dr. Ramy Farid, Ph.D.

President, Chief Executive Officer, Director

Dr. Robert Abel, Ph.D.

Executive Vice President, Chief Scientific Officer, Platform

Dr. Karen Akinsanya, Ph.D.

President - R&D Therapeutics

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Richard A. Friesner, Ph.D.

Director

1.40M

+0.19%

Mr. Kenneth Patrick (Patrick) Lorton

Executive Vice President, Chief Operating Officer - Software

72.66K

+50.36%

Ms. Margaret Dugan, M.D.

Chief Medical Officer

24.57K

-5.68%

Dr. Rosana Kapeller-Libermann, M.D., Ph.D.

Independent Director

11.25K

-8.86%

Mr. Arun Oberoi

Independent Director

11.25K

-8.86%

Ms. Yvonne Tran, J.D.

Chief People Officer, Executive Vice President, Chief Legal Officer

10.49K

-402.13%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de abr

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

On-premise software

101.45M

39.65%

Drug discovery services

54.76M

21.40%

Hosted software

45.12M

17.64%

Software maintenance

27.29M

10.67%

Contribution

15.99M

6.25%

Otro

11.26M

4.40%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

152.96M

59.78%

EMEA

75.16M

29.38%

APAC

26.18M

10.23%

Rest of World

1.56M

0.61%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

On-premise software

101.45M

39.65%

Drug discovery services

54.76M

21.40%

Hosted software

45.12M

17.64%

Software maintenance

27.29M

10.67%

Contribution

15.99M

6.25%

Otro

11.26M

4.40%

Estadísticas de accionistas

Actualizado: lun., 11 de may

Accionistas

Tipos de accionistas

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

12.36%

Bill & Melinda Gates Foundation Trust

10.65%

Rubric Capital Management LP

6.36%

Vanguard Portfolio Management, LLC

5.89%

Amova Asset Management Co., Ltd.

4.87%

Otro

59.87%

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

12.36%

Bill & Melinda Gates Foundation Trust

10.65%

Rubric Capital Management LP

6.36%

Vanguard Portfolio Management, LLC

5.89%

Amova Asset Management Co., Ltd.

4.87%

Otro

59.87%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

42.81%

Investment Advisor/Hedge Fund

26.30%

Hedge Fund

12.61%

Endowment Fund

10.65%

Individual Investor

3.00%

Research Firm

2.77%

Bank and Trust

2.11%

Pension Fund

0.76%

Private Equity

0.31%

Participación institucional



Actualizado: mié., 1 de abr

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2026Q1

525

71.93M

109.89%

-7.22M

2025Q4

534

70.89M

109.90%

-7.48M

2025Q3

545

71.77M

111.28%

-2.08M

2025Q2

572

66.46M

103.14%

-5.60M

2025Q1

593

67.21M

104.69%

-5.43M

2024Q4

576

64.44M

100.89%

-9.04M

2024Q3

581

67.44M

105.91%

-6.15M

2024Q2

573

64.76M

101.80%

-8.12M

2024Q1

574

63.48M

100.05%

-5.40M

2023Q4

584

62.06M

98.56%

-7.64M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

BlackRock Institutional Trust Company, N.A.

8.10M

12.53%

+9.48K

+0.12%

Dec 31, 2025

Bill & Melinda Gates Foundation Trust

6.98M

10.8%

Dec 31, 2025

Rubric Capital Management LP

4.17M

6.45%

-1.10M

-20.83%

Dec 31, 2025

Amova Asset Management Co., Ltd.

4.71M

7.29%

+160.20K

+3.52%

Dec 31, 2025

MFS Investment Management

2.29M

3.54%

+218.92K

+10.56%

Dec 31, 2025

Lazard Asset Management, L.L.C.

2.13M

3.3%

-211.47K

-9.01%

Dec 31, 2025

State Street Investment Management (US)

2.13M

3.3%

-73.13K

-3.32%

Dec 31, 2025

UBS Asset Management (Americas) LLC

2.10M

3.25%

+357.67K

+20.47%

Dec 31, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

ARK Genomic Revolution ETF

3.63%

Clough Select Equity ETF

3.12%

TrueShares Technology, AI & Deep Learning ETF

1.99%

Global X HealthTech ETF

1.14%

State Street SPDR FactSet Innovative Technolgy ETF

0.84%

Franklin Exponential Data ETF

0.82%

WisdomTree BioRevolution Fund

0.77%

Invesco S&P SmallCap Health Care ETF

0.72%

First Trust Nasdaq Lux Digi Health Solutions ETF

0.47%

First Trust Multi-Manager Small Cap Opportunities ETF

0.47%

ARK Genomic Revolution ETF

Proporción3.63%

Clough Select Equity ETF

Proporción3.12%

TrueShares Technology, AI & Deep Learning ETF

Proporción1.99%

Global X HealthTech ETF

Proporción1.14%

State Street SPDR FactSet Innovative Technolgy ETF

Proporción0.84%

Franklin Exponential Data ETF

Proporción0.82%

WisdomTree BioRevolution Fund

Proporción0.77%

Invesco S&P SmallCap Health Care ETF

Proporción0.72%

First Trust Nasdaq Lux Digi Health Solutions ETF

Proporción0.47%

First Trust Multi-Manager Small Cap Opportunities ETF

Proporción0.47%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

KeyAI

